The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market
The Renub Research report titled “The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market” gives a detailed analysis on the global diabetes market. This report investigates the top 10 countries: diabetes prevalence, diabetes drug market and insulin market. It also provides a description of the sales and market share of top 10 brands in anti-obesity drug and diabetes drug market globally. This report talks about the prevalence of Impaired Glucose Tolerance (IGT) globally, 20 countries annual health expenditure on diabetes, death due to type 1 and type 2 diabetes globally.
Market Overview
In recent year’s diabetes drug market and insulin market has shown remarkable growth. This growth is mostly driven by increasing prevalence of diabetes globally and easily availability of insulin in other countries due to its access at an affordable price. The diabetes prevalence is increasing due to changing food habits in the western world leading to obesity.
As the prevalence of obesity and related diseases (diabetes) has increased, so have the sales of drugs to treat them. Top 9 brands of anti-obesity drugs have done sales of more than US$ 100 Million by November 2007 to October 2008. Whereas, top 8 diabetes drug made a sale of more than US$ 5 Billion from the period of October 2007 to October 2008.
Although the works are going on to make the oral-pills an alternative for insulin but at present none of the systems have mimics the physiology of insulin secretion. So it is expected that insulin market will keep on growing to reach US$ 15 Billion by 2012. In future Insulin demand will be driven by countries such as US, China, India, Brazil, Russia and Germany.
Countries Analyzed
World Top 10 diabetic populace countries performances on: diabetes prevalence, diabetes drugs market and insulin market (their past, present and future forecast) have been analyzed in this report. The countries covered in this repot are as follows: United States (US), China, India, Brazil, Russia, Germany, Pakistan, Mexico, Egypt and Japan.
Research Highlights
Key Players
Novo Nordisk A/S, Sanofi-Aventis, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Servier, Bayer AG, Merck & Co., Eli Lilly and Company, Amylin Pharmaceuticals, Inc., Merck KGaA
Data Sources
The information has been collected from various printable and non-pintable sources like Magazines, Newspapers, Trade Journals, White papers, Online paid databases, News websites Government Agencies and Trade associations.
Market Overview
In recent year’s diabetes drug market and insulin market has shown remarkable growth. This growth is mostly driven by increasing prevalence of diabetes globally and easily availability of insulin in other countries due to its access at an affordable price. The diabetes prevalence is increasing due to changing food habits in the western world leading to obesity.
As the prevalence of obesity and related diseases (diabetes) has increased, so have the sales of drugs to treat them. Top 9 brands of anti-obesity drugs have done sales of more than US$ 100 Million by November 2007 to October 2008. Whereas, top 8 diabetes drug made a sale of more than US$ 5 Billion from the period of October 2007 to October 2008.
Although the works are going on to make the oral-pills an alternative for insulin but at present none of the systems have mimics the physiology of insulin secretion. So it is expected that insulin market will keep on growing to reach US$ 15 Billion by 2012. In future Insulin demand will be driven by countries such as US, China, India, Brazil, Russia and Germany.
Countries Analyzed
World Top 10 diabetic populace countries performances on: diabetes prevalence, diabetes drugs market and insulin market (their past, present and future forecast) have been analyzed in this report. The countries covered in this repot are as follows: United States (US), China, India, Brazil, Russia, Germany, Pakistan, Mexico, Egypt and Japan.
Research Highlights
- By 2025 it is expected that India, China and US will be the first, second and third most diabetic populace country.
- In 2005 use of Non-U100 insulin was very popular in India, Ukraine and Egypt its use was more than 50 percent.
- Anti-obesity drug Meridia and Phentermine Hcl combined corner a market share of more than 65 percent globally from the period of November 2007 to October 2008.
- Anti-diabetic drug Actos (product of Takeda) control the highest market share of 40.5 percent globally from the period of October 2007 to October 2008.
- Diabetes drug Actos sale was highest it was more than twice the sale of its nearest competitor Januvia for the period of October 2007 to October 2008.
- Indian diabetic drug market is expected to be more than Rs. 3,200 Crore by 2010.
- Human insulin market in India has been increased to 30 percent in 2007 compared to 25 percent in 2003.
- In India delivery of insulin using cartridges and pen systems is less than 20 percent but it is growing by 35 percent annually.
- China insulin and analogue market grow by 55.8 percent in the year 2007 compared to 2006.
- Russia insulin market is expected to cross the mark of US$ 600 Million by 2010.
- In 2004 Mexico insulin market was just 1 percent of its total pharmaceutical market.
Key Players
Novo Nordisk A/S, Sanofi-Aventis, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Servier, Bayer AG, Merck & Co., Eli Lilly and Company, Amylin Pharmaceuticals, Inc., Merck KGaA
Data Sources
The information has been collected from various printable and non-pintable sources like Magazines, Newspapers, Trade Journals, White papers, Online paid databases, News websites Government Agencies and Trade associations.
1. EXECUTIVE SUMMARY
2. GLOBAL - DIABETES OVERVIEW
2.1 Diabetes Prevalence
2.2 Impaired Glucose Tolerance (IGT)
2.3 Global - Top 10 Countries Performance On
2.3.1 People with Diabetes
2.3.2 Prevalence of Diabetes
2.3.3 Annual Health Expenditure on Diabetes
2.3.4 Death Due to Diabetes
2.4 Diabetes and Obesity Interlinked
2.4.1 Global Top 9 Anti-obesity (systemic) Brand Sales & Market Share
3. GLOBAL MARKET ANALYSIS
3.1 Global Diabetes Prevalence
3.2 Global Diabetes Drugs Market (Past, Present & Future Scenario)
3.2.1 Global Top 10 Diabetes (Non-Insulin) Company, Brand Sales & Market Share
3.3 Global Insulin Market (Past, Present & Future Scenario)
3.3.1 By Region - Types of Insulin Uses
4. TOP 10 COUNTRIES PERFORMANCE
4.1 United States
4.1.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.1.2 Diabetes Drug Market
4.1.3 Insulin Market (Past, Present & Future Scenario)
4.2 China
4.2.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.2.2 Diabetes Drug Market (Past, Present & Future Scenario)
4.2.3 Insulin Market (Past, Present & Future Scenario)
4.3 India
4.3.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.3.2 Diabetes Drug Market (Past, Present & Future Scenario)
4.3.3 Insulin Market (Past, Present & Future Scenario)
4.4 Brazil
4.4.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.4.2 Diabetes Drug Market (Past, Present & Future Scenario)
4.4.3 Insulin Market (Past, Present & Future Scenario)
4.5 Russia
4.5.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.5.2 Insulin Market (Past, Present & Future Scenario)
4.6 Germany
4.6.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.6.2 Insulin Market (Past, Present & Future Scenario)
4.7 Pakistan
4.7.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.8 Mexico
4.8.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.8.2 Insulin Market (Past Scenario)
4.9 Egypt
4.9.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.10 Japan
4.10.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.10.2 Insulin Market (Past, Present & Future Scenario)
5. KEY PLAYERS
5.1 Novo Nordisk A/S
5.2 Sanofi-Aventis
5.3 Takeda Pharmaceutical Company Limited
5.4 GlaxoSmithKline plc
5.5 Servier
5.6 Bayer AG
5.7 Merck & Co.
5.8 Eli Lilly and Company
5.9 Amylin Pharmaceuticals, Inc.
5.10 Merck KGaA
2. GLOBAL - DIABETES OVERVIEW
2.1 Diabetes Prevalence
2.2 Impaired Glucose Tolerance (IGT)
2.3 Global - Top 10 Countries Performance On
2.3.1 People with Diabetes
2.3.2 Prevalence of Diabetes
2.3.3 Annual Health Expenditure on Diabetes
2.3.4 Death Due to Diabetes
2.4 Diabetes and Obesity Interlinked
2.4.1 Global Top 9 Anti-obesity (systemic) Brand Sales & Market Share
3. GLOBAL MARKET ANALYSIS
3.1 Global Diabetes Prevalence
3.2 Global Diabetes Drugs Market (Past, Present & Future Scenario)
3.2.1 Global Top 10 Diabetes (Non-Insulin) Company, Brand Sales & Market Share
3.3 Global Insulin Market (Past, Present & Future Scenario)
3.3.1 By Region - Types of Insulin Uses
4. TOP 10 COUNTRIES PERFORMANCE
4.1 United States
4.1.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.1.2 Diabetes Drug Market
4.1.3 Insulin Market (Past, Present & Future Scenario)
4.2 China
4.2.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.2.2 Diabetes Drug Market (Past, Present & Future Scenario)
4.2.3 Insulin Market (Past, Present & Future Scenario)
4.3 India
4.3.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.3.2 Diabetes Drug Market (Past, Present & Future Scenario)
4.3.3 Insulin Market (Past, Present & Future Scenario)
4.4 Brazil
4.4.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.4.2 Diabetes Drug Market (Past, Present & Future Scenario)
4.4.3 Insulin Market (Past, Present & Future Scenario)
4.5 Russia
4.5.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.5.2 Insulin Market (Past, Present & Future Scenario)
4.6 Germany
4.6.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.6.2 Insulin Market (Past, Present & Future Scenario)
4.7 Pakistan
4.7.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.8 Mexico
4.8.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.8.2 Insulin Market (Past Scenario)
4.9 Egypt
4.9.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.10 Japan
4.10.1 Diabetes Prevalence (Past, Present & Future Scenario)
4.10.2 Insulin Market (Past, Present & Future Scenario)
5. KEY PLAYERS
5.1 Novo Nordisk A/S
5.2 Sanofi-Aventis
5.3 Takeda Pharmaceutical Company Limited
5.4 GlaxoSmithKline plc
5.5 Servier
5.6 Bayer AG
5.7 Merck & Co.
5.8 Eli Lilly and Company
5.9 Amylin Pharmaceuticals, Inc.
5.10 Merck KGaA
LIST OF FIGURES:
2 1: Global - By Region Number of Prevalent Cases of Type 1 Diabetes in Children, (in Thousands) 2007E
Figure 2 2: Global - By Region Number of People with Diabetes, (20-79 age group) (in Millions) 2007 & 2025
Figure 2 3: Global - By Region Prevalence of Diabetes*, (20-79 age group) (in Percent) 2007 & 2025
Figure 2 4: Global - By Region People with Diabetes in different age group (20-39) (40-59) (60-79) (in Millions), 2007
Figure 2 5: Global - By Region Number of People with Impaired Glucose Tolerance (20-79 age group) (in Millions) 2007 & 2025
Figure 2 6: Annual Health Expenditure for Diabetes (ID) vs Persons with Diabetes in the 25 Countries with the Largest Numbers of Persons with Diabetes in 2007
Figure 2 7: Global – By Region Number of Deaths attributable to Diabetes (20-79 age group) (in Millions) 2007
Figure 2 8: Global – By Region Overweight and Obesity among School-age Children (5-17 Years), 2003
Figure 3 1: Global – Diabetes Drug Market (in Billions US$), 2005 – 2007E
Figure 3 2: Global – Diabetes Drug Market (in Billions US$), 2008 – 2010
Figure 3 3: Global – Insulin Market (in Billion US$), 2005 – 2007
Figure 3 4: Global – Insulin Market (in Billion US$), 2008 – 2012
Figure 3 5: Global – By Region Usage of Types of Insulin (Rapid-and fast-acting, Long-and intermediate-acting, Premix, Analogue, U100, Animal), (in Percent), 2005
Figure 3 6: Global - Ukraine, China, Pakistan, Argentina, Brazil & Uruguay – Uses of Animal Insulin (in Percent), 2005
Figure 3 7: Global – Egypt, Hungry, Ukraine, Bangladesh, India, China & Indonesia – Uses of Non-U100 Insulin (in Percent), 2005
Figure 4 1: US - Number of Diagnosed Diabetes Patients (in Million), 2003 - 2007
Figure 4 2: US – Direct and Indirect Cost of Diabetes (in Billion US$), 2007E
Figure 4 3: US - Glucose Strips Markets (in Billion US$), 2006 – 2013F
Figure 4 4: US – Diabetes Drug Market (in Billion US$), 2001 – 2007
Figure 4 5: US – Forecast for Diabetes Drug Market (in Billion US$), 2008 – 2010
Figure 4 6: US – Insulin Market (in Billion US$), 2003 – 2007E
Figure 4 7: US – Forecast for Insulin Market (in Billion US$), 2008 – 2010
Figure 4 8: China - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 9: China – Anti-diabetic Drug Market (in Million Yuan), 2006 – 2007
Figure 4 10: China – Forecast for Anti-diabetic Drug Market (in Million Yuan), 2008 – 2010
Figure 4 11: China – Insulin & Analogue Market (in Million Yuan), 2006 – 2007
Figure 4 12: China – Forecast for Insulin & Analogue Market (in Million Yuan), 2008 – 2010
Figure 4 13: India - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 14: India – Anti-diabetic Drug Market (in Crore Rs), 2002 – 2007
Figure 4 15: India – Forecast for Anti-diabetic Drug Market (in Crore Rs), 2008 – 2010
Figure 4 16: India – Share of Human Insulin Market, Animal Insulin Market & Oral Anti-Diabetic Market (in Percent), 2003 & 2007
Figure 4 17: India - Insulin Market (in Crore Rs), 2003 – 2007
Figure 4 18: India – Forecast for Insulin Market (in Crore Rs), 2008 – 2010
Figure 4 19: India – Uses of Insulin Syringes, Cartridges and Pen Systems (in Percent), 2005
Figure 4 20: Brazil - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 21: Brazil – Oral Anti-diabetic Drug Market (in Million US$), 2000, 2001, 2007E
Figure 4 22: Brazil – Forecast for Oral Anti-diabetic Drug Market (in Million US$), 2008 – 2010
Figure 4 23: Brazil - Insulin Market (in Million US$), 2000, 2001, 2003, 2007E
Figure 4 24: Brazil – Forecast for Insulin Market (in Million US$), 2008 – 2010
Figure 4 25: Russia - Number of Diabetes Patients (in Million), 2005 – 2007
Figure 4 26: Russia - Insulin Market (in Million US$), 2002, 2005 – 2007E
Figure 4 27: Russia – Forecast for Insulin Market (in Million US$), 2008 – 2010
Figure 4 28: Germany - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 29: Germany - Insulin Market (in Million US$), 2004 – 2007
Figure 4 30: Germany – Forecast for Insulin Market (in Million US$), 2008 – 2010
Figure 4 31: Pakistan - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 32: Mexico - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 33: Mexico – Insulin Market (in Million US$ & Percent), 2004
Figure 4 34: Egypt - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 35: Japan - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 36: Japan - Insulin Market (in Million US$), 2005 – 2007
Figure 4 37: Japan – Forecast for Insulin Market (in Million US$), 2008 – 2010
2 1: Global - By Region Number of Prevalent Cases of Type 1 Diabetes in Children, (in Thousands) 2007E
Figure 2 2: Global - By Region Number of People with Diabetes, (20-79 age group) (in Millions) 2007 & 2025
Figure 2 3: Global - By Region Prevalence of Diabetes*, (20-79 age group) (in Percent) 2007 & 2025
Figure 2 4: Global - By Region People with Diabetes in different age group (20-39) (40-59) (60-79) (in Millions), 2007
Figure 2 5: Global - By Region Number of People with Impaired Glucose Tolerance (20-79 age group) (in Millions) 2007 & 2025
Figure 2 6: Annual Health Expenditure for Diabetes (ID) vs Persons with Diabetes in the 25 Countries with the Largest Numbers of Persons with Diabetes in 2007
Figure 2 7: Global – By Region Number of Deaths attributable to Diabetes (20-79 age group) (in Millions) 2007
Figure 2 8: Global – By Region Overweight and Obesity among School-age Children (5-17 Years), 2003
Figure 3 1: Global – Diabetes Drug Market (in Billions US$), 2005 – 2007E
Figure 3 2: Global – Diabetes Drug Market (in Billions US$), 2008 – 2010
Figure 3 3: Global – Insulin Market (in Billion US$), 2005 – 2007
Figure 3 4: Global – Insulin Market (in Billion US$), 2008 – 2012
Figure 3 5: Global – By Region Usage of Types of Insulin (Rapid-and fast-acting, Long-and intermediate-acting, Premix, Analogue, U100, Animal), (in Percent), 2005
Figure 3 6: Global - Ukraine, China, Pakistan, Argentina, Brazil & Uruguay – Uses of Animal Insulin (in Percent), 2005
Figure 3 7: Global – Egypt, Hungry, Ukraine, Bangladesh, India, China & Indonesia – Uses of Non-U100 Insulin (in Percent), 2005
Figure 4 1: US - Number of Diagnosed Diabetes Patients (in Million), 2003 - 2007
Figure 4 2: US – Direct and Indirect Cost of Diabetes (in Billion US$), 2007E
Figure 4 3: US - Glucose Strips Markets (in Billion US$), 2006 – 2013F
Figure 4 4: US – Diabetes Drug Market (in Billion US$), 2001 – 2007
Figure 4 5: US – Forecast for Diabetes Drug Market (in Billion US$), 2008 – 2010
Figure 4 6: US – Insulin Market (in Billion US$), 2003 – 2007E
Figure 4 7: US – Forecast for Insulin Market (in Billion US$), 2008 – 2010
Figure 4 8: China - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 9: China – Anti-diabetic Drug Market (in Million Yuan), 2006 – 2007
Figure 4 10: China – Forecast for Anti-diabetic Drug Market (in Million Yuan), 2008 – 2010
Figure 4 11: China – Insulin & Analogue Market (in Million Yuan), 2006 – 2007
Figure 4 12: China – Forecast for Insulin & Analogue Market (in Million Yuan), 2008 – 2010
Figure 4 13: India - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 14: India – Anti-diabetic Drug Market (in Crore Rs), 2002 – 2007
Figure 4 15: India – Forecast for Anti-diabetic Drug Market (in Crore Rs), 2008 – 2010
Figure 4 16: India – Share of Human Insulin Market, Animal Insulin Market & Oral Anti-Diabetic Market (in Percent), 2003 & 2007
Figure 4 17: India - Insulin Market (in Crore Rs), 2003 – 2007
Figure 4 18: India – Forecast for Insulin Market (in Crore Rs), 2008 – 2010
Figure 4 19: India – Uses of Insulin Syringes, Cartridges and Pen Systems (in Percent), 2005
Figure 4 20: Brazil - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 21: Brazil – Oral Anti-diabetic Drug Market (in Million US$), 2000, 2001, 2007E
Figure 4 22: Brazil – Forecast for Oral Anti-diabetic Drug Market (in Million US$), 2008 – 2010
Figure 4 23: Brazil - Insulin Market (in Million US$), 2000, 2001, 2003, 2007E
Figure 4 24: Brazil – Forecast for Insulin Market (in Million US$), 2008 – 2010
Figure 4 25: Russia - Number of Diabetes Patients (in Million), 2005 – 2007
Figure 4 26: Russia - Insulin Market (in Million US$), 2002, 2005 – 2007E
Figure 4 27: Russia – Forecast for Insulin Market (in Million US$), 2008 – 2010
Figure 4 28: Germany - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 29: Germany - Insulin Market (in Million US$), 2004 – 2007
Figure 4 30: Germany – Forecast for Insulin Market (in Million US$), 2008 – 2010
Figure 4 31: Pakistan - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 32: Mexico - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 33: Mexico – Insulin Market (in Million US$ & Percent), 2004
Figure 4 34: Egypt - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 35: Japan - Number of Diabetes Patients (in Million), 2003 – 2007
Figure 4 36: Japan - Insulin Market (in Million US$), 2005 – 2007
Figure 4 37: Japan – Forecast for Insulin Market (in Million US$), 2008 – 2010
LIST OF TABLES:
Table 2 1: Global – Total Adult Population, Impaired Glucose Tolerance Population & Comparative Prevalence, (20-79 age group) (in Billions, Millions and Percent) respectively 2007 & 2025
Table 2 2: Global – Top 10 Countries Number of People with Diabetes (20-79 age group) (in Millions) 2007 & 2025
Table 2 3: Global – Top 10 Countries in Prevalence of Diabetes (20-79 age group) (in Percent) 2007 & 2025
Table 2 4: Global – Top 9 Anti-obesity (systemic) Brand Sales (in Millions), Market Share & Percentage Change, November 2007 to October 2008
Table 3 1: Global – Number of People with Diabetes & Prevalence (20-79 age group) (in Millions & Percent) 2007 & 2025
Table 3 2: Global – Top 10 Oral Anti-diabetics Market Share & Fixed-rate Growth (in Percent), July 2006 - June 2007
Table 3 3: Global - Top 8 Diabetes (Non-Insulin) Brand Sales (in Millions), Market Share & Percentage Change, October 2007 – October 2008
Table 4 1: US – Forecast for Number of Diagnosed Diabetes Patients (in Million), 2008 - 2025
Table 4 2: China – Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 – 2025
Table 4 3: India – Forecast for Number of Diagnosed Diabetes Patients (in Million), 2008 – 2025
Table 4 4: Brazil – Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 – 2025
Table 4 5: Russia – Forecast for Number of Diabetes Patients (in Millions), 2008 – 2025
Table 4 6: Germany – Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 – 2025
Table 4 7: Pakistan – Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 – 2025
Table 4 8: Mexico – Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 – 2025
Table 4 9: Egypt – Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 – 2025
Table 4 10: Japan - Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 – 2025
Table 5 1: Novo Nordisk A/S – Financial Overview (in Million US$), 2006-2008
Table 5 2: Sanofi-Aventis – Financial Overview (in Million US$), 2005-2007
Table 5 3: Sanofi-Aventis – Financial Overview (in Million US$), 2004-2006
Table 5 4: Sanofi-Aventis – Financial Overview (in Million US$), 2005-2007
Table 5 5: Bayer AG– Financial Overview (in Million US$), 2005-2007
Table 5 6: Merck & Co. - Financial Overview (in Million US$), 2005-2007
Table 5 7: Eli Lilly and Company - Financial Overview (in Million US$), 2005-2007
Table 5 8: Amylin Pharmaceuticals, Inc. - Financial Overview (in Million US$), 2005-2007
Table 5 9: Merck KGaA - Financial Overview (in Million US$), 2005-2007
Table 2 1: Global – Total Adult Population, Impaired Glucose Tolerance Population & Comparative Prevalence, (20-79 age group) (in Billions, Millions and Percent) respectively 2007 & 2025
Table 2 2: Global – Top 10 Countries Number of People with Diabetes (20-79 age group) (in Millions) 2007 & 2025
Table 2 3: Global – Top 10 Countries in Prevalence of Diabetes (20-79 age group) (in Percent) 2007 & 2025
Table 2 4: Global – Top 9 Anti-obesity (systemic) Brand Sales (in Millions), Market Share & Percentage Change, November 2007 to October 2008
Table 3 1: Global – Number of People with Diabetes & Prevalence (20-79 age group) (in Millions & Percent) 2007 & 2025
Table 3 2: Global – Top 10 Oral Anti-diabetics Market Share & Fixed-rate Growth (in Percent), July 2006 - June 2007
Table 3 3: Global - Top 8 Diabetes (Non-Insulin) Brand Sales (in Millions), Market Share & Percentage Change, October 2007 – October 2008
Table 4 1: US – Forecast for Number of Diagnosed Diabetes Patients (in Million), 2008 - 2025
Table 4 2: China – Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 – 2025
Table 4 3: India – Forecast for Number of Diagnosed Diabetes Patients (in Million), 2008 – 2025
Table 4 4: Brazil – Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 – 2025
Table 4 5: Russia – Forecast for Number of Diabetes Patients (in Millions), 2008 – 2025
Table 4 6: Germany – Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 – 2025
Table 4 7: Pakistan – Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 – 2025
Table 4 8: Mexico – Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 – 2025
Table 4 9: Egypt – Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 – 2025
Table 4 10: Japan - Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 – 2025
Table 5 1: Novo Nordisk A/S – Financial Overview (in Million US$), 2006-2008
Table 5 2: Sanofi-Aventis – Financial Overview (in Million US$), 2005-2007
Table 5 3: Sanofi-Aventis – Financial Overview (in Million US$), 2004-2006
Table 5 4: Sanofi-Aventis – Financial Overview (in Million US$), 2005-2007
Table 5 5: Bayer AG– Financial Overview (in Million US$), 2005-2007
Table 5 6: Merck & Co. - Financial Overview (in Million US$), 2005-2007
Table 5 7: Eli Lilly and Company - Financial Overview (in Million US$), 2005-2007
Table 5 8: Amylin Pharmaceuticals, Inc. - Financial Overview (in Million US$), 2005-2007
Table 5 9: Merck KGaA - Financial Overview (in Million US$), 2005-2007
